Paired HIV-1 RNA and Proviral DNA Next-Generation Genotyping in ART-Naïve People with HIV: A Pilot Study of Low-Frequency Drug Resistance Mutations

For more than twenty-five years, doctors treating HIV have relied on a standard test to decide which medicines will work best. This test looks at the genetic code of the virus floating in a patient's blood, known as plasma RNA. It acts like a map, showing which parts of the virus have changed in ways that might make them immune to specific drugs. If the map shows a resistance, doctors can choose a different combination of medicines to ensure the treatment succeeds. However, this traditional method has a blind spot: it can only see the most common versions of the virus. If a tiny, rare version of the virus exists alongside the main one, the test often misses it completely, even if that rare version could eventually take over and cause the treatment to fail.

Scientists have developed a much more sensitive tool called next-generation sequencing. This technology can find those rare, hidden versions of the virus, sometimes spotting them when they make up less than one percent of the total viral population. But this sensitivity creates a new puzzle. When doctors look at the blood of people who have never taken HIV medicine before, they sometimes see a confusing array of these rare mutations. The question is whether these tiny, rare changes matter at all, or if they are just noise—random errors or dead-end viral fragments that cannot actually cause harm. To answer this, researchers recently conducted a study to see what happens when they look for these rare mutations in two different places: the active virus in the blood and the dormant, hidden virus stored inside the body's cells.

The study focused on thirty-five people living with HIV who had never taken antiretroviral therapy. These individuals visited a clinic in Detroit and agreed to have their blood tested before starting any treatment. The researchers collected two types of samples from each person. The first was plasma, the liquid part of the blood where the active virus circulates. The second was a sample of white blood cells, which can harbor the virus in a dormant, DNA-based form that has been integrated into the cell's own genetic material. Using the highly sensitive next-generation sequencing technology, the team analyzed both samples to find any signs of drug resistance. They were looking for specific changes in the virus's genetic code that are known to reduce the effectiveness of common HIV medicines.

The results revealed a striking difference between the two samples. While the researchers found a total of 264 drug resistance mutations across all the participants, the vast majority of these were found in the DNA from the white blood cells, not in the active virus in the plasma. Specifically, nearly 70 percent of the detected mutations came from the DNA samples, while only about 31 percent came from the plasma. Furthermore, most of these mutations were extremely rare, appearing in less than five percent of the viral population. In the plasma samples, almost 80 percent of the mutations were found at these very low levels, and in the DNA samples, about two-thirds were similarly rare. The mutations were most often found in the genetic instructions for two specific classes of drugs: nucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors, which are among the most commonly used treatments today.

The researchers also noticed that many of these rare mutations, especially those found in the DNA, bore the signature of a natural defense mechanism in human cells called APOBEC. This mechanism is designed to mutate and disable invading viruses, but it often leaves behind genetic damage that makes the virus unable to replicate. Because these mutations are likely the result of the body trying to fight the virus rather than the virus evolving to resist drugs, they may not represent a real threat to treatment. When the researchers looked at the data with a stricter lens—ignoring any mutation that appeared in less than five percent of the virus—the number of people appearing to have resistance to multiple drug classes dropped dramatically. In the plasma samples, no one showed resistance to three or four different drug classes once the low-frequency mutations were filtered out. In the DNA samples, the number of people with such complex resistance patterns fell from nearly 70 percent to just 17 percent.

During the 48 weeks of clinical follow-up after participants started their medication, none experienced a rebound of the virus (defined as HIV-1 RNA greater than 50 copies/mL) or had to stop or switch treatment due to adverse effects. However, the study authors note that this pilot analysis did not specifically evaluate the impact of the detected mutations on treatment outcomes, and a follow-up analysis is planned to report on their clinical significance. This suggests that while the sensitive technology can detect a vast landscape of genetic changes, the immediate clinical implications of these low-level changes remain unclear. The study highlights a significant challenge for doctors: the more sensitive the test, the more confusing the results become. A test that sees every tiny variation might suggest that a patient has resistance to almost every drug available, when in reality, the active virus causing the infection might be fully susceptible to standard treatment.

The authors conclude that while this new technology offers a deeper look into the history of the virus inside a person's body, it is not yet clear how to use this information to guide treatment decisions for people starting therapy for the first time. The abundance of rare mutations found in the dormant DNA, many of which are likely harmless or non-functional, creates uncertainty. Doctors need to know which of these tiny signals are warnings of future failure and which are simply background noise. Until more research clarifies the clinical significance of these low-frequency variants, especially those found in the dormant DNA, the standard approach of relying on the active virus in the blood remains the most reliable guide for choosing the right medicines. The study serves as a reminder that in the complex world of HIV, seeing more does not always mean knowing more, and that the most sensitive tools require the most careful interpretation.